Diabetes
Conditions
Keywords
Diabetes, Glucose sensor, Sensor accuracy and performance, CGM
Brief summary
The trial will investigate the accuracy and performance of a new sensor for continuous glucose monitoring (CGM), the (new generation) Enlite, CE-marked in 2013, in conjunction with the new Medtronic 640G system components. To evaluate the accuracy and performance of the new generation Enlite sensor. This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and self-monitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home.
Detailed description
The trial will investigate the accuracy and performance (i.e. the life-time) of a new sensor for CGM, the (new generation) Enlite glucose sensor, CE-marked in 2013, in conjunction with the new Medtronic 640G system components. Accuracy and life-time of the sensor are important parameters contributing to the safety of patients and patient acceptance of this still fairly new technology. The current trial investigates the accuracy of the new sensor in conjunction with the new 640G system components both in the clinic and at home. This enables us to assess the sensor accuracy in a well-controlled environment using a highly accurate laboratory glucose analyzer as reference as well as sensor accuracy during real-life conditions using a blood glucose meter as reference analyzer. The data gathered in this trial will help to understand the effect of technological advancements made and can guide future development of glucose sensor for continuous glucose monitoring.
Interventions
DEVICEGlucose sensor (Enlite)
This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
Sponsors
Profil Institut für Stoffwechselforschung GmbH
Medtronic Diabetes
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 74 Years
Healthy volunteers
No
Inclusion criteria
* Subject has signed the informed consent form prior to screening * Age 18-74 years (both inclusive) * Subject has been diagnosed with T1DM * Subject is current insulin pump user for at least 3 months * HbA1c 9.5% * With the exception of T1DM, the subject is considered generally healthy upon completion of medical history, physical examination, vital signs, ECG and biochemical investigations as judged by the Investigator
Exclusion criteria
* Female of childbearing potential who is pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures include sterilization, hormonal intrauterine devices, oral contraceptives, sexual abstinence, vasectomized partner) * Subject has any condition that, in the opinion of the Investigator or qualified Investigational Centre staff, may preclude him/her from participating in the study and completing study related procedures. * Subject has impaired vision or hearing problems that could compromise the handling of the device as determined by Investigator or qualified Investigational Centre staff * Subject is unable to tolerate tape adhesive in the area of sensor placement * Subject has any unresolved adverse skin condition in the area of sensor placement (e.g. psoriasis, rash, Staphylococcus infection) * Subject has travel plans which would make it difficult for the subject to attend on-site study visits as scheduled * Subject is actively participating in an investigational study (drug or device) wherein he/she has received treatment from an investigational study drug or investigational study device in the last 30 days * Subject known to be positive for Hepatitis B surface antigen (HBsAg) or Hepatitis C antibodies (or diagnosed with active hepatitis according to local practice). * Positive result to the screening test for HIV-1 antibodies, HIV-2 antibodies or HIV-1 antigen according to locally used diagnostic testing * Significant history of alcoholism or drug/chemical abuse as per investigator's judgment, current regular alcohol consumption of more than 1 unit per day for women and more than 2 units per day for men \[1 unit of alcohol equals 1 beer (330 mL), 1 glass of wine (120 mL), or 1 glass of spirits (40 mL)\], or a positive result in the urine drug/alcohol screen at the screening visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Sensor Accuracy | 4 months | Sensor values were compared to YSI plasma glucose values, which is considered as the gold standard, during the frequent sample testing day (day 3). MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) \* 100). |
| Consensus Error Grid Analysis of Paired Sensor and Reference Plasma Glucose Values | 4 months | All analysis performed using the Consensus Error Grid (or Parkes error grid) comparing the paired sensor and YSI reference glucose values. Zone A is defined in the Parkes error grid as the zone of clinical accurate measurements with no effect on clinical action. Zone B as altered clinical action with little or no effect on clinical outcome.. Ideal situation is 100% in Zone A + B. |
| Sensor Survival | 4 months | sensor survival in hours |
Participant flow
Recruitment details
All Subjects
Pre-assignment details
All Subjects
Participants by arm
| Arm | Count |
|---|---|
| All Subjects All Subjects | 24 |
| Total | 24 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 3 |
Baseline characteristics
| Characteristic | All Subjects |
|---|---|
| Age, Continuous | 40.6 Years STANDARD_DEVIATION 13.3 |
| Region of Enrollment Europe | 24 Participants |
| Sex: Female, Male Female | 9 Participants |
| Sex: Female, Male Male | 15 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 24 |
| other Total, other adverse events | 5 / 24 |
| serious Total, serious adverse events | 0 / 24 |
Outcome results
Primary
Consensus Error Grid Analysis of Paired Sensor and Reference Plasma Glucose Values
All analysis performed using the Consensus Error Grid (or Parkes error grid) comparing the paired sensor and YSI reference glucose values. Zone A is defined in the Parkes error grid as the zone of clinical accurate measurements with no effect on clinical action. Zone B as altered clinical action with little or no effect on clinical outcome.. Ideal situation is 100% in Zone A + B.
Time frame: 4 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| All Subjects | Consensus Error Grid Analysis of Paired Sensor and Reference Plasma Glucose Values | 100.0 percentage |
Primary
Sensor Accuracy
Sensor values were compared to YSI plasma glucose values, which is considered as the gold standard, during the frequent sample testing day (day 3). MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) \* 100).
Time frame: 4 months
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| All Subjects | Sensor Accuracy | 9.13 percentage | Standard Deviation 7.14 |
Primary
Sensor Survival
sensor survival in hours
Time frame: 4 months
| Arm | Measure | Value (MEAN) |
|---|---|---|
| All Subjects | Sensor Survival | 130.8 hours |